Anixa Biosciences Net Worth
Anixa Biosciences Net Worth Breakdown | ANIX |
Anixa Biosciences Net Worth Analysis
Anixa Biosciences' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Anixa Biosciences' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Anixa Biosciences' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Anixa Biosciences' net worth analysis. One common approach is to calculate Anixa Biosciences' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Anixa Biosciences' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Anixa Biosciences' net worth. This approach calculates the present value of Anixa Biosciences' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Anixa Biosciences' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Anixa Biosciences' net worth. This involves comparing Anixa Biosciences' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Anixa Biosciences' net worth relative to its peers.
Enterprise Value |
|
To determine if Anixa Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Anixa Biosciences' net worth research are outlined below:
| Anixa Biosciences had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 210 K. Net Loss for the year was (9.93 M) with profit before overhead, payroll, taxes, and interest of 127.5 K. | |
| Anixa Biosciences currently holds about 31.66 M in cash with (6.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.03. | |
| Anixa Biosciences has a frail financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders Equity Non-Compliance |
Anixa Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Anixa Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Anixa Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 12th of June 2024 Next Financial Report | View | |
| 31st of January 2024 Next Fiscal Quarter End | View | |
| 21st of January 2025 Next Fiscal Year End | View | |
| 31st of October 2023 Last Quarter Report | View | |
| 31st of October 2023 Last Financial Announcement | View |
Know Anixa Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Anixa Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Anixa Biosciences backward and forwards among themselves. Anixa Biosciences' institutional investor refers to the entity that pools money to purchase Anixa Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Northern Trust Corp | 2024-09-30 | 71 K | Bank Of New York Mellon Corp | 2024-09-30 | 58.7 K | Corecap Advisors, Llc | 2024-09-30 | 44.8 K | Marshall Wace Asset Management Ltd | 2024-09-30 | 44.5 K | Tyler-stone Wealth Management | 2024-09-30 | 42 K | Cambridge Invest Research Advisors, Inc. | 2024-09-30 | 41.1 K | International Assets Investment Management, Llc | 2024-09-30 | 37.8 K | Ci Private Wealth Llc | 2024-09-30 | 37.4 K | Gemmer Asset Management Llc | 2024-06-30 | 35 K | Vanguard Group Inc | 2024-09-30 | 1.4 M | Davidson D A & Co | 2024-09-30 | 671.1 K |
Follow Anixa Biosciences' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 106.51 M.Market Cap |
|
Project Anixa Biosciences' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.44) | (0.46) | |
| Return On Capital Employed | (0.54) | (0.57) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | (0.46) | (0.49) |
When accessing Anixa Biosciences' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Anixa Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Anixa Biosciences' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Anixa Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Anixa Biosciences. Check Anixa Biosciences' Beneish M Score to see the likelihood of Anixa Biosciences' management manipulating its earnings.
Evaluate Anixa Biosciences' management efficiency
Anixa Biosciences has return on total asset (ROA) of (0.3465) % which means that it has lost $0.3465 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5524) %, meaning that it created substantial loss on money invested by shareholders. Anixa Biosciences' management efficiency ratios could be used to measure how well Anixa Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.46 in 2024. Return On Capital Employed is likely to drop to -0.57 in 2024. At this time, Anixa Biosciences' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 1.2 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 181.4 K in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.87 | 0.82 | |
| Tangible Book Value Per Share | 0.87 | 1.73 | |
| Enterprise Value Over EBITDA | (7.97) | (8.37) | |
| Price Book Value Ratio | 4.63 | 4.39 | |
| Enterprise Value Multiple | (7.97) | (8.37) | |
| Price Fair Value | 4.63 | 4.39 | |
| Enterprise Value | 134.1 M | 134.2 M |
The operational strategies employed by Anixa Biosciences management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Enterprise Value Revenue 368.9827 | Return On Equity (0.55) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Anixa Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Anixa Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Anixa Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Anixa Biosciences Corporate Filings
8K | 8th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 23rd of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 6th of September 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
F3 | 3rd of May 2024 The schedule filed by any person or group who acquires beneficial ownership of more than 5% of a voting class of a company's equity securities registered under Section 12 of the Act | ViewVerify |
Anixa Biosciences Earnings per Share Projection vs Actual
Already Invested in Anixa Biosciences?
The danger of trading Anixa Biosciences is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Anixa Biosciences is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Anixa Biosciences. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Anixa Biosciences is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for Anixa Stock Analysis
When running Anixa Biosciences' price analysis, check to measure Anixa Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anixa Biosciences is operating at the current time. Most of Anixa Biosciences' value examination focuses on studying past and present price action to predict the probability of Anixa Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anixa Biosciences' price. Additionally, you may evaluate how the addition of Anixa Biosciences to your portfolios can decrease your overall portfolio volatility.